黑色素瘤免疫、化疗或靶向治疗患者的血栓栓塞发生率、危险因素与结局
基于SEER-Medicare数据库2008至2019年6218例黑色素瘤患者,比较免疫检查点抑制剂、化疗或靶向治疗启动后2年内血栓栓塞发生率。各治疗类型静脉与动脉血栓栓塞累积发生率相近,血栓栓塞与生存期显著变差相关。
要点
- 免疫、化疗或靶向治疗12个月静脉血栓栓塞累积发生率约7.4%–8.4%,动脉血栓栓塞约5.0%–6.5%。
- 静脉血栓栓塞史和脑转移与静脉血栓栓塞风险升高相关,心血管病、糖尿病、动脉血栓栓塞史和抗血小板治疗与动脉血栓栓塞风险升高相关。
- 静脉或动脉血栓栓塞患者生存期约差2倍,免疫亚组中伊匹木单抗/纳武利尤单抗联合静脉血栓栓塞风险高于纳武利尤单抗。
核心结论
- 免疫检查点抑制剂、化疗和靶向治疗均与黑色素瘤患者高血栓栓塞发生率相关,且血栓栓塞与生存期显著变差相关。
研究设计与样本
- 队列研究,使用SEER-Medicare数据库纳入2008至2019年接受免疫检查点抑制剂、化疗或BRAF/MEK抑制剂治疗的6218例黑色素瘤患者,评估治疗启动后2年内血栓栓塞发生率。
主要发现
- 静脉血栓栓塞史(SHR 2.81,95%CI 2.19-3.61)和脑转移(SHR 1.33,95%CI 1.06-1.66)与静脉血栓栓塞风险升高相关。
- 心血管病(SHR 1.49,95%CI 1.14-1.93)、糖尿病(SHR 1.27,95%CI 1.04-1.57)、动脉血栓栓塞史(SHR 1.61,95%CI 1.13-2.29)和抗血小板治疗(SHR 1.37,95%CI 1.03-1.83)与动脉血栓栓塞风险升高相关。
- 静脉血栓栓塞(HR 2.17,95%CI 1.64-2.87)或动脉血栓栓塞(HR 2.58,95%CI 1.92-3.47)患者生存期约差2倍。
关键数值与推荐
- 与纳武利尤单抗相比,伊匹木单抗/纳武利尤单抗联合(SHR 1.66,95%CI 1.09-2.54)和伊匹木单抗(SHR 1.43,95%CI 1.03-2.00)静脉血栓栓塞风险更高。
- 免疫检查点抑制剂亚组中静脉血栓栓塞(HR 3.24,95%CI 2.30-4.58)和动脉血栓栓塞(HR 1.89,95%CI 1.20-2.99)与更差生存相关。
临床怎么用
- 对接受免疫检查点抑制剂、化疗或靶向治疗的黑色素瘤患者,应关注血栓栓塞风险,尤其存在静脉血栓栓塞史、脑转移、心血管病、糖尿病、动脉血栓栓塞史或抗血小板治疗者。
- 发生静脉或动脉血栓栓塞提示预后更差,需加强监测与综合管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Little is known about venous thromboembolism (VTE) and arterial thromboembolism (ATE) risk in melanoma patients receiving immune checkpoint inhibitors (ICIs) compared with other therapies. OBJECTIVES: We assessed the incidence, risk factors, and impact of thromboembolism (TE) on survival in patients receiving ICIs, chemotherapy, or targeted therapy. METHODS: We conducted a cohort study using the Surveillance, Epidemiology, and End Results-Medicare database to evaluate TE rates in patients treated with ICIs, chemotherapy, or BRAF/MEK inhibitors from 2008 to 2019, within 2 years after treatment initiation. Associations among TE, treatment, and clinical risk factors were evaluated using weighted competing risk regression. Overall survival was estimated by Kaplan-Meier and Cox regression models. RESULTS: Among 6218 patients, 62.1% (n = 3860) received first-line ICIs, 30.4% (n = 1890) received chemotherapy, and 7.5% (n = 468) received targeted therapy. The cumulative incidence of VTE was similar across all treatment types: 7.7% for ICIs, 8.4% for chemotherapy, and 7.4% for targeted therapy at 12 months (P = .80). Similarly, ATE rates were 5.3% for ICIs, 5.0% for chemotherapy, and 6.5% for targeted therapy at 12 months (P = .30). A history of VTE (subdistribution hazard ratio [SHR], 2.81 [95% CI, 2.19-3.61]) and brain metastases (SHR, 1.33 [95% CI, 1.06-1.66]) were associated with an increased risk of VTE. Compared with chemotherapy, ICIs and targeted therapy had a similar VTE risk (P > .05). For ATE, cardiovascular disease (SHR, 1.49 [95% CI, 1.14-1.93]), diabetes mellitus (SHR, 1.27 [95% CI, 1.04-1.57]), a history of ATE (SHR, 1.61 [95% CI, 1.13-2.29]), and antiplatelet therapy (SHR, 1.37 [95% CI, 1.03-1.83]) were associated with increased risk. Patients with VTE or ATE experienced a 2-fold worse survival (hazard ratio [HR], 2.17 [95% CI, 1.64-2.87] and HR, 2.58 [95% CI, 1.92-3.47], respectively). In the ICI subanalysis, the ipilimumab/nivolumab combination had a higher cumulative incidence of VTE: 11.9% at 12 months, 9.3% for ipilimumab, 7.5% for pembrolizumab, and 5.8% for nivolumab (P < .05). Compared with nivolumab, the ipilimumab/nivolumab combination (SHR, 1.66 [95% CI, 1.09-2.54]) and ipilimumab (SHR, 1.43 [95% CI, 1.03-2.00]) had a higher VTE risk. VTE and ATE were associated with worse survival (HR, 3.24 [95% CI, 2.30-4.58] and HR, 1.89 [95% CI, 1.20-2.99], respectively). CONCLUSION: ICIs, chemotherapy, and targeted therapy are associated with a high incidence of TE, and TE is associated with substantially worse survival.
引用
- Sussman TA, Vu L, Koroukian SM, et al. Incidence, risk factors, and outcomes of thromboembolism in patients with melanoma receiving immune checkpoint inhibitors, chemotherapy, or targeted therapy: a Surveillance, Epidemiology, and End Results-Medicare analysis. J Thromb Haemost. 2026. PMID: 42731732. doi:10.1016/j.jtha.2026.09.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。